USPs that matters:

$kyrocking Ca$hcows

AI triggered Signals

ETF InfoDataHub

Visit our new ATH Index-Gate

White Label as a Service

IPO InfoDataHub

Short Selling Radar

Turnkey solutions: ayondo Franchise

& more ...

Tipp: Hedge Fund Activity Tracker ("HFAT")

Newswire
Directors Dealings
DD i/o
Short Selling Radar
HFAT
WWR
FTT
NewAD
Ratings
Vola-Statistics

Tools

Tools/Apps
Lab

Education
Webinars
Mentoring

Press

FAQ

What's New

EN
DE

Company
- About Us
- Vision/Mission
- IR
- Press
- Career
- Specials
Portfolio
Product
- CFD/FX
- Indices
- Currencies
- Commodities
- Metals
- Stocks & ETFs
- Crypto
- ETP/ETI
- Financial Innovations
Platforms
Institutional/B2B

Login Register

Home
Terminal
ANGLE PLC LS-,10

ANGLE PLC LS-,10

WHO'M

ai

Digital Profiler. Simply click the AI button

CUSIP

00857U107

SEDOL

3433067

CIK

N/A

angleplc.com

LEI: 213800BY11K6W3NMS374

New: Infographics X-Lab

FIGI: BBG000L63ZN6

AGL

ANGLE PLC LS-,10

GICS: - · Sector: Health Care · Sub-Sector: Health Care

AI

PROFILER

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

AI

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

ANGLE

Click to initiate

ENTERPRISE

NAME

ANGLE PLC LS-,10

ISIN

GB0034330679

TICKER

AGL

MIC

AIMX

REUTERS

AGL.L

BLOOMBERG

AGL LN

F&G: 35

8.409,91 FTSE · 23,40 Vola-Index · 94.986,51 BTC · 1,34221 GBPUSD

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

X-OVR
FACTSHEET
PEERGROUP
X-News Explorer
L/S SHORT
STUDY
ROOTS
IT’s ME

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

Directors Dealings

X-Billboard

EQS Newswire

Globe Newswire

PR Newswire

BusinessWire

ACCESS Newswire

ActuNews

Newsfile

EDGAR

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by ACCESS Newswire.

Fri, 21.03.2025 ANGLE

GB0034330679

UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACTDevelopment of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay successfully completed for AstraZenecaResults of Eisai Phase 2 pilot study supports the capability of the Parsortix system for real-time assessment of ...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

Fri, 21.03.2025 ANGLE

GB0034330679

GUILDFORD, SURREY / ACCESS Newswire / March 21, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at the Annual General Meeting on 11 July 2024 ("the Remuneration Policy"), the Remuneration Committee has approved the grant under the Lo...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

Wed, 29.01.2025 ANGLE

GB0034330679

NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platformFindings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sampleANGLE invited to present data at EACR-Illumina webinar on 6 February 2025 GUILDFORD, SURREY / ACCESS Newswire / January 29, 2025 / ANGLE pl...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

Fri, 24.01.2025 ANGLE

GB0034330679

CLINICAL TRIAL POWERED BY PARSORTIX SYSTEM PROVIDES FIRST-IN-CLASS data FOR NOVEL APPROACH TO CANCER treatmentParsortix system used to identify patients with highly metastatic CTC clusters for targeted treatmentNew treatment strategy provides 'uncharted opportunity' to target metastasis responsible for the vast majority of cancer deaths GUILDFORD, ...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

Fri, 13.12.2024 ANGLE

GB0034330679

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUMIndependent findings support ANGLE's HER2 assay development programmePotential for stratification of breast cancer patients for treatment with HER2 antibody drug conjugates SURREY, UK / ACCESSWIRE / December 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a w...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

Fri, 15.11.2024 ANGLE

GB0034330679

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug d...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

Fri, 15.11.2024 ANGLE

GB0034330679

RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCEParsortix-based HER2 kit being developed to provide an optimised, easily implemented, solution to enable product customers to undertake longitudinal, repeat assessment of HER2 status in breast cancerGUILDFORD, SURREY / ACCESSWIRE / Novem...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

Wed, 13.11.2024 ANGLE

GB0034330679

PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCETwo posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation of CTCs GUILDFORD, SURREY / ACCESSWIRE / November 13, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

Mon, 11.11.2024 ANGLE

GB0034330679

ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients developing treatment resistance prior to disease progressionCTC analysis identifies druggable targ...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

Thu, 17.10.2024 ANGLE

GB0034330679

PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCERParsortix enriched CTCs detected at high rates in localised diseaseMulti-marker profiling of CTCs could support development of targeted therapies and help stratify patients in clinical trials GUILDFORD, SURREY / ACCESSWIRE / October 17, 2024 / ANGLE plc (AIM:A...

Read More

ANGLE

Technical Analysis Termsheet Terminal

Permalink

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

SMART * AD

EN GIF 970X250

P R O D U C T S U G G E S T I O N S

Report a bug

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Important note

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

Understood and confirmed *

I would like to continue *

Continue

Submit improvement suggestion/new feature

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Link to view/tool

View/Tool (specify URL/link)

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Your opinion is important to us!

FAQ Profile QA Triggered

You are interested

Do you have a request? Get in contact with us

You are already a member?

Who is online? Community stats (Snapshot): 29.411 Visitors - 21.498 Registered members - 18 New registrations (Welcome!)

ayondo® 2025 - Est.: 2008 - Technology provider, social network, trader community and online platform for investors with an affinity for the stock market - Information, data and news network - Multi-award-winning international business model - Proprietary technology - Fintech pioneer and innovation driver for disruptive technologies - Made in Germany | AI First | NextGen-Finovator

Made in Germany

ayondo-prime a²

Useful Links

About Us

Vision/Mission

Imprint

Legal

Terms of service

Data Protection

Cookie Guidelines

Privacy

Contact

MetaTrader 4

MetaTrader 5

ActivTrader

Education

Tools

Product Universe

FAQ

Fast lane

https://ayon.do/v

https://ayon.do/r

ayondo® - my community, my spirit

Social Media Links

Newsletter

ayondo® is a trademark of RSQ Technology Ventures GmbH ("RSQ"). RSQ is the operator of the Internet presence ayondo.com and its sub-sites. ayondo® as a brand represents a community of interest that is connected via a social network and common interests.

Financial literacy represents a key qualification. A key objective is to promote financial knowledge and financial literacy. The content published on the online portal is aimed at people who are interested in information and education in the field of investment, investing and trading and related topics. As a precautionary measure, we would like to point out that none of the content available on ayondo.com can be interpreted as a recommendation or invitation to buy or sell financial instruments, nor does it constitute any other advisory service. An explicit recommendation to use a particular service, information or financial instruments is not made.

Inasmuch as investment brokerage within the meaning of Section 2 (2) No. 3 of the German Securities Trading Act (WpIG) is provided via the online portal ayondo.com, RSQ acts as a contractually bound broker pursuant to Section 3 (2) WpIG. This service is provided exclusively for the account and under the liability of DonauCapital Wertpapier GmbH, Passauer Str. 5, 94161 Ruderting. In this case, the contractual partner of the customer is exclusively DonauCapital Wertpapier GmbH.

RSQ is entered as a contractually bound intermediary of DonauCapital Wertpapier GmbH in the public register maintained by the Federal Financial Supervisory Authority (BaFin) on the Internet. The register can be viewed at www.bafin.de.

If interested parties wish to take advantage of securities services with reference to CFD or FX trading, there is the option to consider offers from our cooperation partners for this purpose. Provided that this option is used, RSQ will broker trading accounts to the ActivTrades group of companies.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of all retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

©ayondo · THE Social Trading Pioneer · FinTech made in Germany · 2025

Consumer information

Imprint

smart.AD

Candlestick Cheatsheet
(02/2023)

Math of Gains and Losses
(02/2023)

FX-Secrets
(02/2023)

Product search
(02/2023)

Risk of Ruin
(03/2023)

Trade Calculator
(03/2023)

Suggest a Product
(03/2023)

Quality Matrix
(03/2023)

ChatGPT ayondo
(02/2023)

GPT-FAQ
(03/2023)

MQL AI
(05/2023)

MQL Library
(06/2023)

Visual Sitemap
(06/2023)

2min's FF
(07/2023)

Vola Hist
(08/2023)

DAX-Statistics
(09/2023)

Technical Analysis
(09/2023)

Technical Analysis-pro
(10/2023)

TransparentShare
(11/2023)

Dashboards^pro
(12/2023)

Most Popular
(12/2023)

Pinned⁺
(12/2023)

Bookmarks⁺
(12/2023)

NYSE A-Z
(12/2023)

PineScript AI
(Q1/2024)

SSR ^{First Timer}
(Q1/2024)

AIT-Dashboard
(Q1/2024)

Trading Simulator
(Q2/2024)

Constituents
(Q2/2024)

X-Billboard
(Q2/2024)